Tech Company Financing Transactions
Agendia Funding Round
On 7/26/2018, Agendia secured $35 million in funding from Athyrium Opportunities Fund.
Transaction Overview
Company Name
Announced On
7/26/2018
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Undisclosed
Investors
Athyrium Opportunities Fund (Jeffrey Ferrell)
Proceeds Purpose
Proceeds from the financing will accelerate commercial expansion in the U.S. and international markets, including increasing adoption of Agendia's recently-launched next-generation sequencing-based MammaPrint BluePrint Breast Cancer Recurrence and Molecular Subtyping Kit.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
22 Morgan
Irvine, CA 92618
USA
Irvine, CA 92618
USA
Phone
Website
Email Address
Overview
Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Straley
Chief Financial Officer
Kurt Becker
Chief Marketing Officer
William Audeh
Chief Scientific Officer
René Bernards
VP - Bus. Development
Bastiaan Baan
VP - Bus. Development
Wendy Blosser
VP - Sales
Laura Veer
Browse more venture capital transactions:
Prev: 7/25/2018: SpotAngels venture capital transaction
Next: 7/26/2018: HealthCrowd venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on all VC transactions involving tech companies. VC investment data records on this site come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs